Wall Street traders expect the $4.5 billion merger between Spain-based Grifols and RTP-based Talecris (Nasdaq: TLCR) to receive U.S. government approval any day now.

So reports Bloomberg news.

“There is a high level of confidence that they’re going to get approval any day,” said Peter Lobravico, New York-based vice president of merger arbitrage trading and sales at Wall Street Access. “I’m still taken aback as to why this has taken so long.”

The deal was announced last June, but the U.S. Federal Trade Commission has yet to grant approval since both firms are such large players in the blood-based therapeutics business.

Last week, Grifols’ chairman said he expected FTC approval. (Read the details here.)

For details, read here.

Get the latest news alerts: Follow WRAL Tech Wire at Twitter.